NewLink Genetics, Inc. (NLNK)

Oncology Corporate Profile

Stock Performance

16.2600
-0.4900

HQ Location

2503 South Loop Drive, Suite 5100
Ames, IA 50010

Company Description

NewLink is a biopharmaceutical company focused on discovering, developing and commercializing novel immuno-oncology products to improve treatment options for patients with cancer. NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens.

Website: http://newlinkgenetics.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Algenpantucel-LimmunotherapyPancreatic cancerIII
indoximodIDO pathway inhibitorBrain MetastasesII
indoximodIDO pathway inhibitorBreast cancerII
Dorgenmeltucel-LimmunotherapyMelanomaII
Tergenpumatucel-LimmunotherapyNon Small Cell Lung Cancer (NSCLC)II
indoximodIDO pathway inhibitorProstate cancerII
indoximodIDO pathway inhibitorAcute Myelogenous Leukemia (AML)I
HyperAcute® ProstateimmunotherapyProstate cancerI
HyperAcute® RenalimmunotherapyRenal cell carcinoma (RCC)I
NL G919IDO pathway inhibitorVarious cancer typesI

View additional information on product candidates here »

Source: http://newlinkgenetics.com

Recent News Headlines

7/20/2017 06:19 pm

7/20/2017 06:19 pm

7/20/2017 06:19 pm

7/20/2017 06:19 pm

7/20/2017 06:19 pm

7/12/2017 12:19 pm

7/12/2017 12:19 pm

7/12/2017 12:19 pm

7/12/2017 12:19 pm

7/12/2017 12:19 pm

7/10/2017 12:19 am

7/10/2017 12:19 am

7/10/2017 12:19 am

7/10/2017 12:19 am

7/7/2017 12:19 am

7/7/2017 12:19 am

7/7/2017 12:19 am

7/7/2017 12:19 am

7/7/2017 12:19 am

6/23/2017 12:19 am

6/21/2017 12:20 pm

6/19/2017 06:19 am

6/18/2017 06:19 am

6/13/2017 06:19 am

6/9/2017 12:19 pm